Request Appointment
Business Strategy
Probingon operates on two complementary commercial tracks: technology licensing and selective device development.
The primary commercial model is technology licensing. FAT-IBC, our validated wireless intrabody communication subsystem, is licensed to OEM manufacturers of implantable medical devices. The OEM carries the clinical programme, the regulatory pathway, and the reimbursement strategy. Probingon provides the communication layer and integration support. Revenue is generated through upfront licence fees, milestone payments tied to OEM regulatory and commercial gates, and royalties on deployed units.
Market entry for the licensing track is driven by the licensee, bringing established clinical networks, regulatory capability, and distribution infrastructure in their target geographies. This keeps Probingon focused on technology delivery and integration engineering.
In parallel, selected technologies from our research platform at Uppsala University advance toward full medical device commercialisation, where clinical evidence and market size justify the longer development timeline. These programmes run primarily on non-dilutive grant funding and do not affect the licensing business financially or operationally.
Where Probingon leads the commercialisation path directly, market entry follows a staged approach: initial adoption through clinical validation partnerships in selected lead markets, expansion through strategic alliances with industry partners across geographies and clinical areas, and full commercial rollout once clinical evidence, regulatory clearance, and distribution partnerships are in place.
Healthcare markets are structurally fragmented across geographies, reimbursement systems, and clinical specialties. Whether through OEM licensing or direct commercialisation, Probingon works through established partners rather than building proprietary commercial infrastructure. This keeps the organisation lean and capital-efficient while accessing global markets through partners who already operate in them.
Investor? Our business model is licensing-first, not device development. See our Investors page →